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INTRODUCTION

23
Episodic tension-type headache (ETTH) is the most common form of headache disorder and 24 accounts up to 78% of all headache disorders [1] . ETTH typically causes mild to moderate 25 dull pain that radiates in a band-like fashion bilaterally and occurs usually less than 15 days 26
per month for at least 3 months. Prevalence rate of ETTH varies widely ranging from 29 to 27 71 percent among studies, and is most commonly seen in young adults over 20 years of age 28
[2]. ETTH is caused by muscle contractions in the head, face, neck and shoulders, which 29 are usually related to stress, fatigue, emotional conflicts, depression or repressed hostility.
30
Tension headaches are usually self-treated with over-the-counter (OTC) analgesics, of 31 which paracetamol is one of those most frequently used. Caffeine has also demonstrated to 32
have an analgesic adjuvant effect in combination with paracetamol to provide significantly 33 superior headache relief [3] . 34 35
Fast relief of pain, within ≤30 minutes of dosing, is an essential requirement for ETTH 36 sufferers [4] [5] [6] [7] [8] . Several approaches have previously been utilized in an attempt to achieve a 37 rapidly absorbed paracetamol solid dose formulation [9] [10] . Inclusion of sodium bicarbonate 38 in the caplets, which has a prokinetic effect on gastric emptying rate, offers an effective 39 approach for increasing the rate of absorption of paracetamol from oral dosage forms [11-40 12] . 41 42
To enhance the speed of absorption of paracetamol and caffeine to help pain relief more 43 rapidly, a combination of paracetamol and caffeine (RAPC) in a sodium bicarbonate caplet 44 formulation has been developed. No data has been previously published on the effect of 45 sodium bicarbonate for the absorption of both paracetamol and caffeine. The present pivotal 46 pharmacokinetic (PK) study was conducted to assess bioequivalence and rate of absorption 47 for both paracetamol and caffeine between the new RAPC formulation (total dose of two 48 tablets containing 1000 mg paracetamol + 130 mg caffeine + 650 mg sodium bicarbonate) 49 and currently marketed Panadol ® Extra tablets (total dose of two tablets containing 1000 mg 50 paracetamol + 130 mg caffeine). 51 52
MATERIAL AND METHODS
54
Subjects 55
Potential subjects willing to participate in the study were recruited from the site's database of 56 potential volunteers, referrals and Institutional Review Board (IRB) approved advertising. To 57 be eligible of participation in the study, the subjects were required to be of 18-55 years of 58 age, with a body mass index (BMI) of 18-30 kg/m 2 (both inclusive), in good general health, 59
who could understand and were willing, able and likely to comply with all the study 60 procedures and restrictions. The females of child-bearing potential were required to practice 61 a reliable method of contraception during the study.
63
The subjects were excluded if they were intolerant or hypersensitive to the study drug, were 64 taking any prescription/ herbal/ OTC medication 7 days prior to dosing, or using any enzyme 65 inducing drug 30 days prior to screening. Subjects were also excluded if they smoked more 66 than 5 cigarettes a day, had donated blood within 3 months of the screening visit, or had 67 donated more than 1500ml of blood within 12 months of prior to dosing. Vegetarian subjects 68
were also excluded from the study. Additionally, subjects who consumed beverages 69 containing grapefruit/seville oranges or marmalade/ or had caffeine containing drinks or food 70 24 hours prior to dosing, and who had undertaken any unusually strenuous physical activity 71 24 hours prior to the screening and admission, were also excluded.
73
All subjects were informed with objectives, drugs, potential risks, dates and activities prior to 74 their participation. A written consent form was signed by each subject. 75 76
The study was conducted in accordance with the ethical principles of Declaration of Helsinki 77
[ The study drugs were administered two hours after eating a standard meal, which is 102 considered to be a realistic scenario in clinical practice. Subjects ate breakfast 2 hours 103 before dosing for the semi-fed state and were restricted from having breakfast in the morning 104 for the fasted state. In addition, no food or drink was allowed after midnight for fasted state.
105
The content of all the meals were standardized with respect to protein, carbohydrate and fat 106 content and the timings of meals and drinks were standardized. 107 108
Blood Sampling 109
The blood samples were withdrawn either from an indwelling cannula or venapuncture 110 (situated in a forearm vein) and transferred into 4.9 lithium heparinized polypropylene 111 monovettes. A 1 ml discard was taken from the cannula prior to sampling and the cannula 112 was flushed after sampling with approximately 1 ml heparinized saline. 113 114
Blood samples were centrifuged at approximately 3000 revolutions per minute (rpm) at 115 approximately 4 Celsius (°C) for approximately 15 minutes. Approximately 2.5 ml plasma 116 was separated from each sample and transferred equally into two 5 ml polypropylene screw 117 top tubes. Plasma samples were stored in tubes labelled with the study number, 118 randomization number, study session and time point of the blood sample and frozen at 119 approximately -20°C within 1 hour of sampling. 120 121
The samples were collected at pre-dose and at different time points through 10 hours post-122 dose (pre-dosing, 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 5, 6, 7 and 10 hours post dose). A wash-123 out period of 48 hours was chosen between adjacent doses to allow for elimination of any 124 metabolites. Total of approximately 360 ml of blood was collected from each study 125 participants throughout the study, of which approximately 274 ml (14 x 4.9 ml x 4) was used 126 for PK analysis. 127
Paracetamol and caffeine in plasma was analyzed by using a validated High Performance Secondary PK parameters including AUC 0-30min , AUC 0-60min, and T max were analyzed using 162 non-parametric method Wilcoxon signed-rank test. The 95% confidence intervals for median 163 of differences were calculated based on Hodges-Lehmann method. These tests were 164 performed at 5% level of significance. 165
166
In addition, AUC 0-30min , AUC 0-60min and T c≥4ug/ml were analyzed using parametric methods as 167 described for primary parameters above. 168 169
Safety evaluation 170
The safety and tolerability of the study treatments was based on adverse events (AEs) 171
reported by all subjects following dosing with study formulations. 172 173
RESULTS
175 Demography
Of the 81 subjects screened for this study, 30 were randomized, and 28 of the randomized 177 subjects completed all four periods of the study. All the randomized subjects completed at 178 least one treatment period of the study. 179 180
A total of 20 (66.7%) males and 10 (33.3%) females participated in the study. All of these 181 subjects were Caucasian. The mean age was 34 years (range 22 to 48 years). The mean 182 weight was 67.89 kg (range 48.1 to 88.3 kg), and the mean height was 164.5 cm (range 146 183 to 182 cm). The average BMI was reported as 25 kg/m 2 (range 20.2 to 29.5 kg/m 2 ). 184
Pharmacokinetic Results
185
The mean plasma paracetamol and caffeine concentration versus time curves for both 186 treatments in the fasted and semi-fed states are presented in Figure 1 Results for bioequivalence assessment by using PK parameters are summarized in Table 1  206 and Table 2 for paracetamol and caffeine, respectively. In the fasted state, the exposure to 207 paracetamol for RAPC was bioequivalent to Panadol ® Extra for AUC 0-10 hrs and AUC 0-∞ with 208 90% confidence intervals (CIs), all being within the range 0.80 to 1.25 (Table 1 ). The two 209 treatments were not bioequivalent for C max in fasted state (Table 1) . For exposure to 210 caffeine, RAPC was bioequivalent to Panadol ® Extra for AUC 0-10 hrs, AUC 0-∞ and C max in 211 fasted state (Table 2) . 212 213
In the semi-fed state, the exposure to paracetamol for RAPC was bioequivalent to Panadol ® 214 Extra for AUC 0-10 hrs , AUC 0-∞ and C max with 90% confidence intervals (CIs), all contained 215 within the range 0.80 to 1.25 (Table 1) . RAPC was also bioequivalent to Panadol ® Extra for 216 AUC 0-10 hrs , AUC 0-∞ and C max in reference to the exposure of caffeine (Table 2) . AUC 0-60 min ) and T max in both fasted and semi-fed states by using non-parametric/parametric 236 method (excluding T max ) are given in Table 3A/3B and Table 4A/4B for paracetamol and  237 caffeine, respectively. 238 239
In fasted state for paracetamol, RAPC had a significantly greater exposure for AUC 0-30 min 240
and AUC 0-60 min (p <0.0001) and T max was significantly shorter (by ~29 minutes, pP <0.0001) 241 than Panadol ® Extra (Table 3A) . Similar results were found in the semi-fed state for exposure 242 to paracetamol, AUC 0-30 min and AUC 0-60 min were significantly greater and T max was 243 significantly shorter for RAPC (by ~30 minutes, P<0.05p=0.0198) than Panadol ® Extra 244 (Table 3A) . 245
In the fasted state for caffeine, RAPC showed a significantly higher exposure for AUC 0-30 min 246
and AUC 0-60 min (p =0.0009P<0.01 and P<0.010.0003, respectively) and T max was significantly 247
shorter (by ~15 minutes, P<0.01p=0.0013) than Panadol ® Extra (Table 4A) . Similarly, in the 248 semi-fed state for exposure to caffeine, AUC 0-30 min and AUC 0-60 min were significantly greater 249 and T max was significantly shorter for RAPC (by ~30 minutes, P<0.05p=0.0403) than 250 Panadol ® Extra (Table 4A) . 251
Similar results were obtained based on the extra analysis for the secondary parameters, 252 AUC 0-30 min and AUC 0-60 min . In both fasted and semi-fed states, for exposure to paracetamol 253 and caffiene, RAPC was superior to the Panadol Extra (Table 3B & Table 4B ). 254 4 T C≥4µg/ml is time to reach plasma paracetamol concentration equal or greater than 4µg/ml. 300 301 min and T max was significantly shorter (by ~15 minutes, p = 0.001) than Panadol ® Extra (Table  303 4). Similarly, in the semi-fed state for exposure to caffeine, AUC 0-30 min and AUC 0-60 min were 304 greater and T max was significantly shorter for RAPC (by ~30 minutes, P = 0.04) than 305 Panadol ® Extra (Table 4) . 306 307
Similar results were obtained based on the extra analysis for the secondary parameters, 308 AUC 0-30 min and AUC 0-60 min . In both fasted and semi-fed states, for exposure to paracetamol 309 and caffiene, RAPC was superior to the Panadol Extra (Table 3B & Table 4B ). 310 311 
